Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)-Reference-Cited by-同舟云学术

Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Published:2023-07-07 Issue:10 Volume:58 Page:1084-1088
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Gavriilaki Eleni^ORCID,Sakellari Ioanna,Labopin Myriam^ORCID,Bornhäuser Martin,Hamladji Rose-Marie,Casper Jochen,Edinger Matthias,Zák Pavel,Yakoub-Agha Ibrahim^ORCID,Ciceri Fabio^ORCID,Schroeder Thomas,Zuckerman Tsila^ORCID,Kobbe Guido,Yeshurun Moshe,Narni Franco^ORCID,Finke Jürgen^ORCID,Diez-Martin Jose Luiz,Berceanu Ana,Hilgendorf Inken^ORCID,Verbeek Mareike,Olivieri Attilio,Savani Bipin,Spyridonidis Alexandros,Nagler Arnon^ORCID,Mohty Mohamad^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-02028-x.pdf

Reference24 articles.

1. Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217–39. https://doi.org/10.1038/s41409-022-01691-w.

2. Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651–64. https://doi.org/10.1038/s41409-021-01227-8.

3. Poiani M, Labopin M, Battipaglia G, Beelen DW, Tischer J, Finke J, et al. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96:40–50. https://doi.org/10.1002/ajh.26000.

4. Zhu S, Liu G, Liu J, Chen Q, Wang Z. Long-term outcomes of treosulfan- vs. busulfan-based conditioning regimen for patients with myelodysplastic syndrome and acute myeloid leukemia before hematopoietic cell transplantation: a systematic review and meta-analysis. Front Oncol. 2020;10:591363 https://doi.org/10.3389/fonc.2020.591363.

5. Sakellari I, Gavriilaki E, Mallouri D, Batsis I, Varelas C, Tagara S, et al. Survival advantage of treosulfan plus fludarabine before allogeneic hematopoietic cell transplantation for older or comorbid patients with myeloid malignancies. Transpl Cell Ther. 2021;27:916.e911–916. https://doi.org/10.1016/j.jtct.2021.07.020.